Partner Headlines - AMRN

  1. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  2. Week Concludes With S&P 500 Below 2,000; Dow Below 17,000

    Benzinga
  3. Dow Falls Over 100 Points; Ulta Salon Shares Jump After Earnings ...

    Benzinga
  4. Conversant Shares Rise On Acquisition News; Health Care REIT ...

    Benzinga
  5. Markets Drop; Darden Adjusted Profit Beats Street View

    Benzinga
  6. Morning Market Losers

    Benzinga
  7. Amarin Moves Higher On Speculation Of Special Protocol Assessment

    Benzinga
  8. Top Performing Industries For June 12, 2014

    Benzinga
  9. FDA Approvals And Changes For The Week Ending February 14, 2 ...

    Benzinga
  10. Amarin Announces FDA DMEP Does Not Plan to Re-instate ANCHOR ...

    Benzinga
  11. Benzinga's Top #PreMarket Losers

    Benzinga
  12. Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement ...

    Benzinga
  13. FDA Delays Decision on Amarin's Vascepa Drug

    Benzinga
  14. Amarin Receives FDA Notification That Action on ANCHOR sNDA Review ...

    Benzinga
  15. Amarin's Vascepa: Too Limited A Market Or FDA Blunder?

    Benzinga
  16. Amarin Announces Notification of Patent Allowances Related to ...

    Benzinga
  17. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  18. Is Amarin’s Fish Oil Blockbuster Dream Kaput?

    YCharts
  19. UPDATE: Citigroup Upgrades Amarin on Valuation

    Benzinga
  20. Benzinga's Top Upgrades

    Benzinga
  21. Aegis Capital Corp. Reiterates on Amarin Corporation plc After ...

    Benzinga
  22. Market Wrap For Thursday, October 17: S&P Record High On Debt ...

    Benzinga
  23. Mid-Day Market Update: SanDisk Surges On Upbeat Results; IBM ...

    Benzinga
  24. Mid-Morning Market Update: Markets Open Lower; Goldman Sachs ...

    Benzinga
  25. Stocks Hitting 52-Week Lows

    Benzinga
  26. UPDATE: Aegis Capital Downgrades Amarin Following Negative Panel ...

    Benzinga
  27. Benzinga's Top Pre-Market Losers

    Benzinga
  28. Amarin Announces Negative FDA Advisory Committee Outcome for ...

    Benzinga
  29. Amarin Halted Ahead of FDA Advisory Committee to Review sNDA ...

    Benzinga
  30. Aegis Says FDA's Outlook 'Not As Negative As People Think' on ...

    Benzinga
  31. Aegis Capital Reiterates Buy on Amarin Corporation Following ...

    Benzinga
  32. Jefferies Reiterates Buy on Amarin Corporation on Continued Positive ...

    Benzinga
  33. Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory ...

    Benzinga
  34. Amarin Shares Up 5% as FDA Says October 16th Advisory Committee ...

    Benzinga
  35. Enrollment in Amarin REDUCE-IT Cardiovascular Outcomes Study ...

    Benzinga
  36. Amarin Reports 30th Patent for Vascepa

    Benzinga
  37. Amarin Submits Supplemental NDA for Novasep as Fourth Vascepa ...

    Benzinga
  38. UPDATE: Citigroup Raises PT on Amarin Following Lighter 2Q13 ...

    Benzinga
  39. UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership ...

    Benzinga
  40. Amarin Announces USPTO Allowance for Application 13/614,129 Related ...

    Benzinga
  41. Amarin Announces Patent Allowance Related to Vascepa and FDA ...

    Benzinga
  42. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  43. Benzinga's Top Pre-Market Gainers

    Benzinga
  44. Amarin Completes Dosing in a Fixed-Dose Combination Study With ...

    Benzinga
  45. Amarin Closes Dosing in Fixed-Dose Combination Study with Vascepa

    Benzinga
  46. FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status ...

    Benzinga
  47. Benzinga's Top Pre-Market Gainers

    Benzinga
  48. Amarin Receives Patent Allowance for Application 13/623,450 Related ...

    Benzinga
  49. Amarin Announces David Stack Appointed to Board of Directors

    Benzinga
  50. Amarin Spikes Lower

    Benzinga
  51. UDPATE: Aegis Capital Raises PT on Amarin to $35

    Benzinga
  52. Citigroup Reiterates Buy Rating, $20 PT on Amarin Corporation

    Benzinga
  53. Benzinga's Top Pre-Market Losers

    Benzinga
  54. UPDATE: Citigroup Initiates Amarin at Buy on Vascepa Overhang ...

    Benzinga
  55. Benzinga's Top Pre-Market Gainers

    Benzinga
  56. Amarin Awarded Patent 8,318,715 for Vascepa by USPTO

    Benzinga
  57. Amarin Announces USPTO has Published Notification of Notice of ...

    Benzinga
  58. A Peek Into The Market Before The Trading Starts

    Benzinga
  59. Amarin Announces US Patent 8,314,086 Award for Vascepa

    Benzinga
  60. Mid-Morning Market Update: Markets Rallying; J.C. Penney Misses ...

    Benzinga
  61. Amarin Awarded US Patent 8,298,554 Issuance for Vascepa

    Benzinga
  62. UPDATE: Wedbush Securities Downgrades Amarin Corporation to Neutral, ...

    Benzinga
  63. Benzinga's M&A Chatter for Tuesday September 11, 2012

    Benzinga
  64. Benzinga's M&A Chatter for Thursday September 6, 2012

    Benzinga
  65. Amarin Announces Notification of Patent Allowances for U.S. Applications ...

    Benzinga
  66. Amarin Announces Notification of Patent Allowance for Vascepa ...

    Benzinga
  67. Amarin Announces Additional Publication of MARINE Phase 3 Clinical ...

    Benzinga
  68. Health Care Sector Wrap

    FoxBusiness
  69. Benzinga's Top Pre-Market Gainers

    Benzinga
  70. Health Care Sector Wrap

    FoxBusiness
  71. Health Care Sector Wrap

    FoxBusiness
  72. Amarin Corporation (AMRN) Sees Spike in Option Activity with ...

    MarketIntelligenceCenter
  73. Amarin's

    IBD
  74. Facebook Inc. - Class A, Starbucks Among Stocks Down on High ...

    FoxBusiness
  75. Amarin Announces FDA Approval of Vascepa Capsules for the Reduction ...

    Benzinga
  76. Amarin and Horizon Pharma Higher Ahead of PDUFA Dates

    Benzinga
  77. Health Care Sector Wrap

    FoxBusiness
  78. Amarin Responds to Erroneous Website Posting

    Benzinga
  79. Biotechs With Upcoming PDUFA Dates

    Benzinga
  80. UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, ...

    Benzinga
  81. New Annual Highs: AMRN, DIS, and NWS

    SchaeffersResearch
  82. Health Care Sector Wrap

    FoxBusiness
  83. Amarin (AMRN) Gains 10.5% As Company Appears Close to Winning ...

    MarketIntelligenceCenter
  84. Amarin Corporation plc, Loral Space & Communications Gapping ...

    FoxBusiness
  85. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT ...

    Benzinga
  86. CF Industries Holdings, SBA Communications Corporation Included ...

    FoxBusiness
  87. AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus ...

    Benzinga
  88. Amarin Corporation plc (AMRN) Sees Above Average Option Activity ...

    MarketIntelligenceCenter
  89. Earnings Scheduled For May 8

    Benzinga
  90. Amarin

    IBD
  91. Amarin (AMRN) Up 20% on Patent News, Analyst Commentary

    MarketIntelligenceCenter
  92. Amarin Up 7% After FDA Announces it Will Not Convene FDA Panel ...

    Benzinga
  93. AMRN said the FDA accepted a new drug for review, while OII updated ...

    SchaeffersResearch
  94. Benzinga's M&A Chatter for Tuesday December 6, 2011

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!